Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis

Annals of the Rheumatic Diseases

Volumn 66, Issue SUPPL. 3, 2007, Pages

  Vasilopoulos, Y ^a   Gkretsi, V ^a   Armaka, M ^a   Aidinis, V ^a   Kollias, G ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; TUMOR NECROSIS FACTOR;

APOPTOSIS; CELL MIGRATION; CELL PROLIFERATION; CONFERENCE PAPER; CYTOSKELETON; DYNAMICS; FIBROBLAST; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

ACTINS; ARTHRITIS, RHEUMATOID; CELL DIVISION; CELL MOVEMENT; CYTOSKELETON; FIBROBLASTS; GENE EXPRESSION; HUMANS; MODELS, BIOLOGICAL; SYNOVIAL MEMBRANE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35648994476     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.079822     Document Type: Conference Paper

References (92)

1. Silman AJ, Pearson JE. Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 2002;4(Suppl 3):S265-72.
2. Tak PP. Examination of the synovium and synovial fluid. In: Firestein GS, Panayi GS, Wollheim FA, eds. Rheumatoid arthritis. Frontiers in pathogenesis and treatment. New York: Oxford University Press, 2000:55-68.
3. Firestein GS. Rheumatoid synovitis and pannus. In: Klippel JH, Dieppe PA, eds. Rheumatology. London: Mosby, 1998:5.13.1-24.
4. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
5. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007;6:75-92.
6. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
7. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993;36:1681-90.
8. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-98.
9. Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999;169:175-94.
10. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594- 602.
11. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
12. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332-7.
13. Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-51.
14. Kontoyiannis D, Kollias G. Fibroblast biology: synovial fibroblasts in rheumatoid arthritis - leading role or chorus line? Arthritis Res 2000;2:342-3.
15. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci USA 2002;99:12877-82.
16. Ritchlin C. Fibroblast biology: effector signals released by the synovial fibroblast in arthritis. Arthritis Res 2000;2:356-60.
17. Lopez-Bote JP, Bernabeu C, Marquet A, Fernandez JM, Larraga V. Adjuvant-induced polyarthritis. Synovial cell activation prior to polyarthritis onset. Arthritis Rheum 1988;31:769-75.
18. Marinova-Mutafchieva L, Williams RO, Funa K, Maini RN, Zvaifler NJ. Inflammation is preceded by tumor necrosis factor-dependent infiltration of mesenchymal cells in experimental arthritis. Arthritis Rheum 2002;46:507-13.
19. Butler DM, Piccoli DS, Hart PH, Hamilton JA. Stimulation of human synovial fibroblast DNA synthesis by recombinant human cytokines. J Rheumatol 1988;15:1463-70.
20. Dayer JM, Krane SM, Russell RG, Robinson DR. Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci USA 1976;73:945-9.
21. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996;149:1607-15.
22. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J 1991;10:4025-31.
23. Aidinis V, Plows D, Haralambous S, Armaka M, Papadopoulos P, Kanaki MZ, et al. Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res 2003;5:R140-57.
24. Firestein GS. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum 1996;39:1781-90.
25. Taniguchi K, Kohsaka H, Inoue N, Terada Y, Ito H, Hirokawa K, et al. Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis. Nat Med 1999;5:760-7.
26. Kullmann F, Widmann T, Kirner A, Justen HP, Wessinghage D, Dietmaier W, et al. Microsatellite analysis in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis 2000;59:386-9.
27. Woerner SM, Kloor M, von Knebel Doeberitz M, Gebert JF. Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark 2006;2:69-86.
28. Aplan PD. Causes of oncogenic chromosomal translocation. Trends Genet 2006;22:46-55.
29. Muller-Ladner U, Gay RE, Gay S. Activation of synoviocytes. Curr Opin Rheumatol 2000;12:186-94.
30. Qu Z, Garcia CH, O'Rourke LM, Planck SR, Kohli M, Rosenbaum JT. Local proliferation of fibroblast-like synoviocytes contributes to synovial hyperplasia. Results of proliferating cell nuclear antigen/cyclin, c-myc, and nucleolar organizer region staining. Arthritis Rheum 1994;37:212- 20.
31. Xue C, Takanashi M, Hasunuma T, Aono H, Yamamoto K, Yoshino S, et al. Characterisation of fibroblast-like cells in pannus lesions of patients with rheumatoid arthritis sharing properties of fibroblasts and chondrocytes. Ann Rheum Dis 1997;56:262-7.
32. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002;99:10025-30.
33. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
34. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
35. Pap T, Franz JK, Hummel KM, Jeisy E, Gay R, Gay S. Activation of synovial fibroblasts in rheumatoid arthritis: lack of expression of the tumour suppressor PTEN at sites of invasive growth and destruction. Arthritis Res 2000;2:59-64.
36. Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor kappaB in synovial inflammation. Curr Rheumatol Rep 2002;4:201-7.
37. Franz JK, Pap T, Hummel KM, Nawrath M, Aicher WK, Shigeyama Y, et al. Expression of sentrin, a novel antiapoptotic molecule, at sites of synovial invasion in rheumatoid arthritis. Arthritis Rheum 2000;43:599-607.
38. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nat Rev Immunol 2002;2:527-35.
39. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 2002;61:934-6.
40. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 2003;62(Suppl 2):ii60-7.
41. Lafyatis R, Remmers EF, Roberts AB, Yocum DE, Sporn MB, Wilder RL. Anchorage-independent growth of synoviocytes from arthritic and normal joints. Stimulation by exogenous platelet-derived growth factor and inhibition by transforming growth factor-beta and retinoids. J Clin Invest 1989;83:1267-76.
42. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004;118:277-9.
43. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54.
44. Zvaifler NJ. Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases. Arthritis Res Ther 2006;8:210.
45. Taketazu F, Kato M, Gobl A, Ichijo H, ten Dijke P, Itoh J, et al. Enhanced expression of transforming growth factor-beta s and transforming growth factor-beta type II receptor in the synovial tissues of patients with rheumatoid arthritis. Lab Invest 1994;70:620-30.
46. Pohlers D, Beyer A, Koczan D, Wilhelm T, Thiesen HJ, Kinne RW. Constitutive upregulation of the TGF-b pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther 2007;9:R59.
47. Kasperkovitz PV, Timmer TC, Smeets TJ, Verbeet NL, Tak PP, van Baarsen LG, et al. Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis. Arthritis Rheum 2005;52:430-41.
48. Mattey DL, Dawes PT, Nixon NB, Slater H. Transforming growth factor beta 1 and interleukin 4 induced alpha smooth muscle actin expression and myofibroblast-like differentiation in human synovial fibroblasts in vitro: modulation by basic fibroblast growth factor. Ann Rheum Dis 1997;56:426-31.
49. Bauer S, Jendro MC, Wadle A, Kleber S, Stenner F, Dinser R, et al. Fibroblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res Ther 2006;8:R171.
50. Steenvoorden MM, Tolboom TC, van der Pluijm G, Lowik C, Visser CP, DeGroot J, et al. Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics. Arthritis Res Ther 2006;8:R165.
51. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436:123-7.
52. Konttinen YT, Li T-F, Hukkanen M, Ma J, Xu J-W, Virtanen I. Fibroblast biology: signals targeting the synovial fibroblast in arthritis. Arthritis Res 2000;2:348-55.
53. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996;134:793-9.
54. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996;84:345-57.
55. Lelievre SA, Bissell MJ, Pujuguet P. Cell nucleus in context. Crit Rev Eukaryot Gene Expr 2000;10:13-20.
56. Aidinis V, Carninci P, Armaka M, Witke W, Harokopos V, Pavelka N, et al. Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS Genet 2005;1:e48.
57. Giganti A, Friederich E. The actin cytoskeleton as a therapeutic target: state of the art and future directions. Prog Cell Cycle Res 2003;5:511-25.
58. Wang J, Sanger JM, Sanger JW. Differential effects of Latrunculin-A on myofibrils in cultures of skeletal muscle cells: insights into mechanisms of myofibrillogenesis. Cell Motil Cytoskeleton 2005;62:35-47.
59. Kulms D, Dussmann H, Poppelmann B, Stander S, Schwarz A, Schwarz T. Apoptosis induced by disruption of the actin cytoskeleton is mediated via activation of CD95 (Fas/APO-1). Cell Death Differ 2002;9:598-608.
60. Puck TT, Krystosek A. Role of the cytoskeleton in genome regulation and cancer. Int Rev Cytol 1992;132:75-108.
61. Disanza A, Steffenc A, Hertzoga M, Frittoli E, Rottnerd K, Scitaa G. Actin polymerization machinery: the finish line of signaling networks, the starting point of cellular movement. Cell Mol Life Sci 2005;62:955-70.
62. Castellano F, Le Clainche C, Patin D, Carlier M, Chavrier P. A WASP-VASP complex regulates actin polymerization at the plasma membrane. Embo J 2001;20:5603-14.
63. Krause M, Bear J, Loureiro J, Gertler F. The Eno/VASP enigma. J Cell Sci 2002;115:4721-6.
64. Kwiatkowski AV, Gertler FB, Loureiro JJ. Function and regulation of Ena/VASP proteins. Trends Cell Biol 2003;13:386-92.
65. Li J, Brieher WM, Scimone ML, Kang SJ, Zhu H, Yin H, et al. Caspase-11 regulates cell migration by promoting Aip1-Cofilin-mediated actin depolymerization. Nat Cell Biol 2007;9:276-86.
66. Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, et al. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol 2001;2:138-45.
67. Bishop A, Hall A. Rho GTPases and their effector proteins. Biochem J 2000;348:241-55.
68. Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14.
69. Ridley AJ. Rho family proteins: coordinating cell responses. Trends Cell Biol 2001;11:471-7.
70. Small JV, Stradal T, Vignal E, Rottner K. The lamellipodium: where motility begins. Trends Cell Biol 2002;12:112-20.
71. Xu H, Liu P, Liang L, Danesh FR, Yang X, Ye Y, et al. RhoA-mediated, tumor necrosis factor alpha-induced activation of NF-kappaB in rheumatoid synoviocytes: inhibitory effect of simvastatin. Arthritis Rheum 2006;54:3441-51.
72. Are AF, Galkin VE, Pospelova TV, Pinaev GP. The p65/RelA subunit of NF-kappaB interacts with actin-containing structures. Exp Cell Res 2000;256:533-44.
73. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007;315:1006-10.
74. Vartiainen MK, Guettler S, Larijani B, Treisman R. Nuclear actin regulates dynamic subcellular localization and activity of the SRF cofoctor MAL. Science 2007;316:1749-52.
75. Schratt G, Philippar U, Berger J, Schwarz H, Heidenreich O, Nordheim A. Serum response factor is crucial for actin cytoskeletal organization and focal adhesion assembly in embryonic stem cells. J Cell Biol 2002;156:737-50.
76. Southwick FS, Dabiri GA, Stossel TP. Neutrophil actin dysfunction is a genetic disorder associated with partial impairment of neutrophil actin assembly in three family members. J Clin Invest 1988;82:1525-31.
77. Procaccio V, Salazar G, Ono S, Styers ML, Gearing M, Davila A, et al. A mutation of β-actin that alters depolymerization dynamics is associated with autosomal dominant developmental malformations, deafness, and dystonia. Am J Hum Genet 2006;78:947-60.
78. Gearing M, Juncos JL, Procaccio V, Gutekunst CA, Marino-Rodriguez EM, Gyure KA, et al. Aggregation of actin and cofilin in identical twins with juvenile-onset dystonia. Ann Neurol 2002;52:465-76.
79. Bamburg JR, Wiggan OP. ADF/cofilin and actin dynamics in disease. Trends Cell Biol 2002;12:598-605.
80. de la Chapelle A, Tolvanen R, Boysen G, Santavy J, Bleeker-Wagemakers L, Maury CPJ, et al. Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 1992;2:157-60.
81. Vallon R, Freuler F, Desta-Tsedu N, Robeva A, Dawson J, Wenner P, et al. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J Immunol 2001;166:2801-7.
82. Lee MS, Yoo SA, Cho CS, Suh PG, Kim WU, Ryu SH. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J Immunol 2006;177:5585-94.
83. Akiyama T, Kawasaki Y. Wnt signalling and the actin cytoskeleton. Oncogene 2006;25:7538-44.
84. Vasiliev J. Cytoskeletal mechanisms responsible for invasive migration of neoplastic cells. Int J Dev Biol 2004;48:425-39.
85. Avizienyte E, Wyke A, Jones R, McLean G, Westho VM, Brunton V, et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling. Nat Cell Biol 2002;4:632-8.
86. Bryant D, Stow JL. The ins and outs of E-cadherin trafficking. Trends Cell Biol 2004;14:427-34.
87. Attwell S, Roskelley C, Dedhar S. The integrin-linked kinase (ILK) suppresses anoikis. Oncogene 2000;19:3811-5.
88. Dai DL, Makretsov N, Campos EI, Huang C, Zhou Y, Huntsman D, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003;9:4409-14.
89. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005;5:51-63.
90. Kato K, Shiozawa T, Mitsushita J, Toda A, Horiuchi A, Nikaido T, et al. Expression of the Mitogen-Inducible Gene-2 (mig-2) is elevated in human uterine leiomyomas but not in leiomyosarcomas. Hum Pathol 2004;35:55-60.
91. Yoganathan TN, Costello P, Chen X, Jabali M, Yan J, Leung D, et al. Integrin-linked kinase (ILK): a "hot" therapeutic target. Biochem Pharmacol 2000;60:1115-9.
92. Spector I, Shochet NR, Blasberger D, Kashman Y. Latrunculins - novel marine macrolides that disrupt microfilament organization and affect cell growth: I. Comparison with cytochalasin D. Cell Motil Cytoskeleton 1989;13:127-44.